Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study

被引：0
|
作者：
Andreas Straube
Gregor Broessner
Charly Gaul
Xenia Hamann
Joachim Hipp
Torsten Kraya
Lars Neeb
机构：
[1] University Hospital,Department of Neurology
[2] LMU Munich,Department of Neurology
[3] Innsbruck Medical University,Department of Neurology
[4] Headache Center Frankfurt,Department of Neurology
[5] Teva GmbH,Department of Neurology
[6] Hospital Sankt Georg Leipzig gGmbH,undefined
[7] Headache Center Halle,undefined
[8] University Hospital Halle,undefined
[9] Helios Global Health,undefined
[10] Charité-Universitätsmedizin Berlin,undefined
来源：
The Journal of Headache and Pain | / 24卷
关键词：
Fremanezumab; Calcitonin gene-related peptide; Migraine; Non-responder;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Real-world Adherence to Subsequent CGRP mAb Treatment Among Chronic Migraine Patients Initially Treated With OnabotulinumtoxinA: A Retrospective Claims Analysis
    Dong, Yanan
    Gusovsky, Amanda
    Shah, Darshini
    Park, Tae Jin
    Zhao, Changgeng
    [J]. TOXICON, 2024, 237 : 22 - 22
  • [22] Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
    Driessen, Maurice T.
    Cohen, Joshua M.
    Thompson, Stephen F.
    Patterson-Lomba, Oscar
    Seminerio, Michael J.
    Carr, Karen
    Totev, Todor, I
    Sun, Rochelle
    Yim, Erica
    Mu, Fan
    Ayyagari, Rajeev
    [J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [23] Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
    Maurice T. Driessen
    Joshua M. Cohen
    Stephen F. Thompson
    Oscar Patterson-Lomba
    Michael J. Seminerio
    Karen Carr
    Todor I. Totev
    Rochelle Sun
    Erica Yim
    Fan Mu
    Rajeev Ayyagari
    [J]. The Journal of Headache and Pain, 2022, 23
  • [24] Real-world effectiveness & safety of fremanezumab in migraine: 3rd interim analysis of the pan-European PEARL study
    Ashina, M.
    Mitsikostas, D.
    Amin, F.
    Kokturk, P.
    Schankin, C.
    Sahin, G.
    Pozo-Rosich, P.
    Dorman, P.
    Nezadal, T.
    Poole, A.
    Martins, I.
    Sumelahti, M.
    Campos, V. Ramirez
    Ning, X.
    Lyras, L.
    Tassorelli, C.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 149 - 150
  • [25] Real-World effectiveness and safety of fremanezumab in migraine: 3rd interim analysis of the pan-european PEARL study
    Ashina, M.
    Mitsikostas, D. D.
    Amin, F. Mohammad
    Kokturk, P.
    Schankin, C. J.
    Sahin, G.
    Pozo-Rosich, P.
    Dorman, P.
    Nezadal, T.
    Poole, A. Christine
    Martins, I. Pavao
    Sumelahti, M. L.
    Campos, V. Ramirez
    Ning, X.
    Lyras, L.
    Tassorelli, C.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [26] Real-world effectiveness after initiating fremanezumab treatment of 165 migraine patients in a regional headache center in Japan
    Kikui, Shoji
    Danno, Daisuke
    Miyahara, Junichi
    Sugyama, Hanako
    Ota, Kuniko
    Murakata, Kenji
    Kashiwaya, Yoshihiro
    Takeshima, Takao
    [J]. CEPHALALGIA, 2023, 43 (1supp) : 236 - 236
  • [27] CGRP Targeting Therapy for Chronic Migraine-Evidence from Clinical Trials and Real-world Studies
    Wang, Yen-Feng
    Wang, Shuu-Jiun
    [J]. CURRENT PAIN AND HEADACHE REPORTS, 2022, 26 (07) : 543 - 554
  • [28] Real-world Adherence to Subsequent CGRP mAb Treatment Among Chronic Migraine (CM) Patients Initially Treated with OnabotulinumtoxinA: A Retrospective Claims Analysis
    Dong, Yanan
    Gusovsky, Amanda
    Shah, Darshini
    Park, Tae Jin
    Zhao, Changgeng
    [J]. NEUROLOGY, 2023, 100 (17)
  • [29] Effectiveness of Switching to Mepolizumab from Other Biologics in Asthma Patients: A Real-World Analysis
    Corbridge, Thomas
    Stach-Klysh, Alexandra
    Lalibert, Francois
    Hilts, Annalise
    Zhang, Kaixin
    Urosevic, Ana
    Deb, Arijita
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB103 - AB103
  • [30] Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for chronic migraine in a US tertiary headache center
    Cohen, Fred
    Yuan, Hsiangkuo
    Dent, Kathryn
    Beucherie, Matthew
    Connolly, William
    Driessen, Maurice
    Krasenbaum, Lynda J.
    Carr, Karen
    Hopkins, Mary
    Marmura, Michael
    [J]. CEPHALALGIA, 2022, 42 (1_SUPPL) : 127 - 128
12345